Effectiveness of ixekizumab and secukinumab: 12-month interim descriptive analysis of the Psoriatic Arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT)
Introduction: Ixekizumab (IXE) and secukinumab (SECU) are IgG4 and IgG1 monoclonal antibodies inhibiting interleukin-17A (IL-17A) approved for multiple indications including PsA. Real-world data on the effectiveness of IL-17A inhibitors for the management of PsA domains is scarce. PRO-SPIRIT aims to [for full text, please go to the a.m. URL]
Institutions
- University of Leeds (GB)
- Eli Lilly (United States) (US)
- Frederiksberg Hospital (DK)
- Düsseldorf University Hospital (DE)
- German Rheumatism Research Centre (DE)
- Eli Lilly (Germany) (DE)
- Schlosspark-Klinik (DE)
- Orthopädische Praxis (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-18
- DOI
- https://doi.org/10.3205/24dgrh180
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00